NCT Number: NCT00038935
Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
The purpose of this study is to determine the relative bioavailability of ReFacto AF as compared to ReFacto, when each is administered as 2-minute bolus infusions.
Looking for future studies?
Notify MeKey information
Conditions
Age range
12 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Severe hemophilia A (FVIII:C < 1% at local laboratory)
- Previously treated patients (PTP) with at least 250 exposure days to any factor VIII product
- Age greater than or equal to 12 years\\
Exclusion criteria
- The presence of any bleeding disorder in addition to hemophilia A
- Concomitant therapy with immunosuppressant drugs (e.g., intravenous immunoglobulin (IVIG), routine systemic corticosteroid use)
- History of detectable factor VIII inhibitor
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
A Single Dose, Randomized, Double-Blind, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of B-Domain Deleted Recombinant Human Factor VIII (BDDrFVIII) Manufactured by the Current Process (ReFacto) and by an Albumin Free Manufacturing Process (ReFacto AF)
Important dates
- Primary completion
- 2003
- Study completion
- 2003
- First posted
- Jun 7, 2002
- Registry last updated
- Apr 22, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
NCT05147662
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Orlando, Florida, United States
View Trial DetailsPharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
NCT06579144
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Sofia, Bulgaria
View Trial DetailsEfficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
NCT03315455
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, China
View Trial DetailsA Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
NCT04158648
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Los Angeles, California, United States
View Trial Details